The interaction of host and pathogen factors in chronic obstructive pulmonary disease exacerbations and their role in tissue damage

Proceedings of the American Thoracic Society

Volumn 4, Issue 8, 2007, Pages 611-617

  Abusriwil, Hatem ^a   Stockley, Robert A ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Bacterial; COPD; Inflammation; Lung damage

Indexed keywords

LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; PROTEINASE; PYOCYANINE; REACTIVE OXYGEN METABOLITE; VIRULENCE FACTOR;

ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; LUNG INJURY; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

BACTERIA; COLONY COUNT, MICROBIAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 37349124177     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200706-065TH     Document Type: Article

References (96)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
2. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003;22:931-936.
3. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
4. McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A, MacGowan A. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001;4:370-375.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
6. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
7. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-364.
8. 1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-1809.
9. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005;26:846-852.
10. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-1320.
11. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-1645.
12. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl JMed 2002;347:465-471.
13. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121.
14. Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. 2006. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006;129:317-324.
15. Currie DC, Pavia D, Agnew JE, Lopez-Vidriero MT, Diamond PD, Cole PJ, Clarke SW. Impaired tracheobronchial clearance in bronchiectasis. Thorax 1987;42:126-130.
16. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998;113:1542-1548.
17. Möller LV, Timens W, van der Bij W, Kooi K, de Wever B, Dankert J, van Alphen L. Haemophilus Influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 1998;157:950-956.
18. Doring G, Goldstein W, Roll A, Schiotz PO, Hoiby N, Botzenhart K. Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis. Infect Immun 1985;49:557-562.
19. Dunn MM, Dunne M, Kamp DW. Polymorphonuclear leukocyte- and Pseudomonas aeruginosa-induced damage to a human pulmonary epithelial cell line. J Infect Dis 1990;162:172-177.
20. Venaille TJ, Ryan G, Robinson BW. Epithelial cell damage is induced by neutrophil-derived, not Pseudomonas-derived, proteases in cystic fibrosis sputum. Respir Med 1998;92:233-240.
21. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14:336-363.
22. Suter S. The role of bacterial proteases in the pathogenesis of cystic fibrosis. Am J Respir Crit Care Med 1994;150:S118-S122.
23. Okamoto T, Akaike T, Suga M, Tanase S, Horie H, Miyajima S, Ando M, Ichinose Y, Maeda H. Activation of human matrix metalloproteinases by various bacterial proteinases. J Biol Chem 1997;272:6059-6066.
24. Morihara K, Tsuzuki H, Oda K. Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma α 1-proteinase inhibitor. Infect Immun 1979;24:188-193.
25. Britigan BE, Railsback MA, Cox CD. The Pseudomonas aeruginosa secretory product pyocyanin inactivates α 1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease. Infect Immun 1999;67:1207-1212.
26. Ras G, Wilson R, Todd H, Taylor G, Cole P. Effect of bacterial products on neutrophil migration in vitro. Thorax 1990;45:276-280.
27. Lopez A, Yong S. Injury versus inflammatory response in the lungs of rats intratracheally inoculated with bacterial lipopolysaccharide. Am J Vet Res 1986;47:1287-1292.
28. Massion PP, Inoue H, Richman-Eisenstat J, Grunberger D, Jorens PG, Housset B, Pittet JF, Wiener-Kronish JP, Nadel JA. Novel Pseudomonas product stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest 1994;93:26-32.
29. Denning GM, Wollenweber LA, Railsback MA, Cox CD, Stoll LL, Britigan BE. Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells. Infect Immun 1998;66:5777-5784.
30. Blue CE, Paterson GK, Kerr AR, Berge M, Claverys JP, Mitchell TJ. ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor a production in the respiratory tract. Infect Immun 2003;71:4925-4935.
31. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway in-flammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:991-998.
32. Schmeck B, Gross R, N'Guessan PD, Hocke AC, Hammerschmidt S, Mitchell TJ, Rosseau S, Suttorp N, Hippenstiel S. Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium. Infect Immun 2004;72:4940-4947.
33. Rajan S, Cacalano G, Bryan R, Ratner AJ, Sontich CU, van Heerckeren A, Davis P, Prince A. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am J Respir Cell Mol Biol 2000;23:304-312.
34. Naylor EJ, Bakstad D, Biffen M, Thong B, Calverley P, Scott S, Hart CA, Moots RJ, Edwards SW. Haemophilus influenzae induces neutrophil necrosis: a role in chronic obstructive pulmonary disease? Am J Respir Cell Mol Biol 2007;37:135-143.
35. Zheng T, Kang MJ, Crothers K, Zhu Z, Liu W, Lee CG, Rabach LA, Chapman HA, Homer RJ, Aldous D, et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-γ-induced alveolar remodeling and pulmonary emphysema. J Immunol 2005;174:8106-8115.
36. Onofrio JM, Toews GB, Lipscomb MF, Pierce AK. Granulocytealveolar- macrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis 1983;127:335-341.
37. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-295.
38. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300.
39. Bakri F, Brauer AL, Sethi S, Murphy TF. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002;185:632-640.
40. Sethi S, Wrona C, Grant BJB, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448-453.
41. Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, de Groot R, Hermans PWM. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004;72:818-823.
42. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006;3:109-115.
43. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160:S49-S52.
44. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-2004.
45. MacNee W. Oxidants/antioxidants and COPD. Chest 2000;117(5 Suppl 1):303S-317S.0
46. Yigla M, Berkovich Y, Nagler RM. Oxidative stress indices in COPD: broncho-alveolar lavage and salivary analysis. Arch Oral Biol 2007;52:36-43.
47. Rahman I, Skwarska E, MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax 1997;52:565-568.
48. Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91.
49. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-1119.
50. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-1060.
51. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:356-361.
52. Wilson R, Roberts D, Cole P. Effect of bacterial products on human ciliary function in vitro. Thorax 1985;40:125-131.
53. Read RC, Wilson R, Rutman A, Lund V, Todd HC, Brain AP, Jeffery PK, Cole PJ. Interaction of nontypable Haemophilus influenzae with human respiratory mucosa in vitro. J Infect Dis 1991;163:549-558.
54. Feldman C, Anderson R, Cockeran R, Mitchell T, Cole P, Wilson R. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro. Respir Med 2002;96:580-585.
55. Smallman LA, Hill SL, Stockley RA. Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax 1984;39:663-667.
56. Tournier JM, Jacquot J, Puchelle E, Bieth JG. Evidence that Pseudomonas aeruginosa elastase does not inactivate the bronchial inhibitor in the presence of leukocyte elastase: studies with cystic fibrosis sputum and with pure proteins. Am Rev Respir Dis 1985;132:524-528.
57. Padrines M, Bieth JG. Pseudomonas aeruginosa elastase does not inactivate a 1-proteinase inhibitor in the presence of leukocyte elastase. Infect Immun 1989;57:3793-3797.
58. Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, Stockley RA, Cole PJ. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991;4:26-32.
59. Ramphal R, Sadoff JC, Pyle M, Silipigni JD. Role of pili in the adherence of Pseudomonas aeruginosa to injured tracheal epithelium. Infect Immun 1984;44:38-40.
60. Gupta SK, Berk RS, Masinick S, Hazlett LD. Pili and lipopolysaccharide of Pseudomonas aeruginosa bind to the glycolipid asialo GM1. Infect Immun 1994;62:4572-4579.
61. Prince A. Flagellar activation of epithelial signaling. Am J Respir Cell Mol Biol 2006;34:548-551.
62. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFNγ-mediated macrophage killing. J Immunol 2005;175:7512-7518.
63. Adler KB, Hendley DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 1986;125:501-514.
64. Malloy JL, Veldhuizen RA, Thibodeaux BA, O'Callaghan RJ, Wright JR. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. Am J Physiol Lung Cell Mol Physiol 2005;288:L409-L418.
65. Alcorn JF, Wright JR. Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol Chem 2004;279:30871-30879.
66. Azghani AO. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol 1996;15:132-140.
67. Johnson GG, Morris JM, Berk RS. The extracellular protease from Pseudomonas aeruginosa exhibiting elastase activity. Can J Microbiol 1967;13:711-719.
68. Kon Y, Tsukada H, Hasegawa T, Igarashi K, Wada K, Suzuki E, Arakawa M, Gejyo F. The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in a rat air pouch inflammation model. FEMS Immunol Med Microbiol 1999;25:313-321.
69. Miyazaki S, Matsumoto T, Tateda K, Ohno A, Yamaguchi K. Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice. J Med Microbiol 1995;43:169-175.
70. Wilson R, Pitt T, Taylor G, Watson D, MacDermot J, Sykes D, Roberts D, Cole P. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 1987;79:221-229.
71. Wilson R, Sykes DA, Watson D, Rutman A, Taylor GW, Cole PJ. Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun 1988;56:2515-2517.
72. Ras GJ, Anderson R, Taylor GW, Savage JE, Van Niekerk E, Wilson R, Cole PJ. Proinflammatory interactions of pyocyanin and 1-hydroxyphenazine with human neutrophils in vitro. J Infect Dis 1990;162:178-185.
73. Baker NR, Minor V, Deal C, Shahrabadi MS, Simpson DA, Woods DE. Pseudomonas aeruginosa exoenzyme S is an adhesion. Infect Immun 1991;59:2859-2863.
74. Wiener-Kronish JP, Sakuma T, Kudoh I, Pittet JF, Frank D, Dobbs L, Vasil ML, Matthay MA. Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits. J Appl Physiol 1993;75:1661-1669.
75. Alaoui-El-Azher M, Jia J, Lian W, Jin S. ExoS of Pseudomonas aeruginosa induces apoptosis through a Fas receptor/caspase 8-independent pathway in HeLa cells. Cell Microbiol 2006;8:326-338.
76. Epelman S, Neely GG, Ma LL, Gjomarkaj M, Pace E, Melis M, Woods DE, Mody CH. Distinct fates of monocytes and T cells directly activated by Pseudomonas aeruginosa exoenzyme S. J Leukoc Biol 2002;71:458-468.
77. Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by Pseudomonas aeruginosa lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1. Infect Immun 2002;70:1352-1358.
78. Holm BA, Keicher L, Liu MY, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991;71:317-321.
79. Read RC, Roberts P, Munro N, Rutman A, Hastie A, Shryock T, Hall R, McDonald-Gibson W, Lund V, Taylor G, et al.. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 1992;72:2271-2277.
80. Somerville M, Taylor GW, Watson D, Rendell NB, Rutman A, Todd H, Davies JR, Wilson R, Cole P, Richardson PS. Release of mucus glycoconjugates by Pseudomonas aeruginosa rhamnolipid into feline trachea in vivo and human bronchus in vitro. Am J Respir Cell Mol Biol 1992;6:116-122.
81. Soong G, Muir A, Gomez MI, Waks J, Reddy B, Planet P, Singh PK, Kaneko Y, Wolfgang MC, Hsiao YS, et al. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J Clin Invest 2006;116:2297-2305.
82. Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987;135:869-874.
83. Paton JC, Ferrante A. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun 1983;41:1212-1216.
84. Rubins JB, Charboneau D, Fasching C, Berry AM, Paton JC, Alexander JE, Andrew PW, Mitchell TJ, Janoff EN. Distinct roles for pneumolysin's cytotoxic and complement activities in the pathogenesis of pneumococcal pneumonia. Am J Respir Crit Care Med 1996;153:1339-1346.
85. Rubins JB, Duane PG, Clawson D, Charboneau D, Young J, Niewoehner DE. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun 1993;61:1352-1358.
86. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor a and interleukin-1 b by human mononuclear phagocytes. Infect Immun 1994;62:1501-1503.
87. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 1984;43:1085-1087.
88. Tong HH, Blue LE, James MA, DeMaria TF. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. Infect Immun 2000;68:921-924.
89. Kilian M, Mestecky J, Schrohenloher RE. Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun 1979;26:143-149.
90. Oggioni MR, Memmi G, Maggi T, Chiavolini D, Iannelli F, Pozzi G. Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia. Mol Microbiol 2003;49:795-805.
91. Geme JWS. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion. Cell Microbiol 2002;4:191-200.
92. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a State-of-the-Art Review. Clin Microbiol Rev 2001;14:336-363.
93. Johnson AP, Inzana TJ. Loss of ciliary activity in organ cultures of rat trachea treated with lipo-oligosaccharide from Haemophilus influenzae. J Med Microbiol 1986;22:265-268.
94. Clemans DL, Bauer RJ, Hanson JA, Hobbs MV, St. Geme JW III, Marrs CF, Gilsdorf JR. Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae. Infect Immun 2000;68:4430-4440.
95. Berenson CS, Murphy TF, Wrona CT, Sethi S. Outer membrane protein p6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infect Immun 2005;73:2728-2735.
96. Sullivan A, Stockley RA. Proteinases in COPD. In: Hansel TT, Barnes PJ, editors. Recent advances in the pathology of COPD. Basel, Switzerland: Birkhauser; 2004.